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Objective: The predicted outcomes of autogenous arteriovenous (AV) hemodialysis access 
creation are predominantly based on historical data; however both the hemodialysis 
population and clinical practices have changed significantly over the last decade. This study 
examined contemporary AV access clinical use and patencies. 
Methods: A multi-centre observational cohort study was performed of all new AV accesses 
created in Scotland in 2015. The primary endpoint was efficacy assessed by successful AV 
access use for a minimum of 30 days and primary, primary-assisted, and secondary patency at 
1 year. Data obtained included all interventions to maintain or restore patency. Predictors of 
patency loss including demographics, comorbid conditions, dialysis status, AV access 
location, duplex surveillance, procedures, prior access, and antiplatelets were assessed. 
Kaplan-Meier and competing risks analyses were performed to estimate the probability of 
AV access failure. All patients were followed-up for at least 1 year, or had a censoring event. 
Results: A total of 582 AV accesses were created in 537 patients (mean age 60 [SD 14] 
years; 60% men; 42% with diabetes) in nine adult renal centres. Mean follow-up was 11.8 
(SD 7.6) months. By the end of the follow-up, 322 (55.3%) AV accesses were successfully 
used for dialysis. At 1 year, 48% (95% CI 44-52) of AV accesses had primary patency, 67% 
(95% CI 63-71) had primary-assisted patency, and 69% (95% CI 65-73) had secondary 
patency. The leading cause of primary patency loss was primary failure (30%). An average of 
0.48 interventions per patient-year was required to maintain patency. On multivariable 
analysis, patency was better for an upper compared to forearm AV access (1-year secondary 
patency of upper vs. forearm AV accesses 74% vs. 58%, respectively). The cumulative 
hazard and incident functions for AV access failure were 31% (95% CI 27-35) and 23% 
(95% CI 20-27) at 1 year, respectively. 
Conclusions: Despite advances in recent years with pre-operative vessel assessment and 
surveillance, patency rates have not improved with primary failure remaining the major 
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obstacle. Competing events should be taken into consideration otherwise biases may occur 
with overestimation of the probability of AV access failure. 
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Introduction 
Autogenous arteriovenous (AV) accesses are widely recognized as the most reliable and 
durable AV access for hemodialysis (HD) treatment. In recent years, however, there have 
been significant changes in the demographics of the prevalent hemodialysis population with 
trends towards increasing age and comorbidity. These changes make successful creation and 
maintenance of AV accesses considerably more challenging.    
A major problem with AV accesses is the high frequency of primary failure, either as a result 
of poor maturation or early thrombosis. Thereafter maintaining AV access patency may be 
compromised by emergent structural or functional problems that may develop during routine 
use1-3. As such, AV access dysfunction is one of the leading causes of morbidity and 
mortality among end stage renal disease patients4-6. Consequently there has been an increased 
focus on percutaneous and surgical interventions aimed at promoting AV access maturation 
and maintaining the long-term patency7. 
Reports of AV access patency and complications are limited by heterogeneous patency 
definitions, the exclusion of primary failures in the estimation of patencies, and the inclusion 
of AV accesses created in the era before the routine uptake of duplex ultrasound (US) for 
vascular mapping and surveillance, or before the shift towards current clinical practice 
patterns which involve more aggressive endovascular interventions. These features contribute 
to wide estimates of secondary patency reported in the literature with data ranging from 45-
96% at 1 year8, 9. Obtaining accurate data that reflect on AV access performance using robust 
definitions is therefore required, and would serve to inform patient and clinician decision 
making, as well as provide benchmarking levels from which standards of care may be set. 
The aim of this study was to assess the outcome of all AV access creation operations by 
determining subsequent successful use and patency in a contemporary non-selected 
population. The natural history of patients following AV access creation, access-related 
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complications, procedure burden, predictors of patency loss and the probability of AV access 
failure were also examined. Data were collected across a variety of centre sizes and 
population types without case-selection, thus these data reflect the outcomes of AV access in 
reality rather than a selected cohort. 
 
Methods 
Study design, participants and setting 
This was a national multi-centre cohort study of all patients in Scotland who underwent 
autogenous arteriovenous (AV) access creation in 2015. All nine renal units in Scotland 
(estimated population of 5,373,000 in 2015) participated with an overall incident HD 
population of 8.1/100,000 between 2012 and 2016. On 31st December 2015 the prevalent HD 
population size was 1,873 with 43% and 75% of the incident and prevalent HD patients, 
respectively, dialysing via AV access10. All adult (aged over 18 years) patients who had 
undergone autogenous AV access creation were identified by cross referencing unitary 
electronic patient records, surgical logbooks, theatre lists and vascular access coordinators 
diaries. Nonautogenous AV accesses and autogenous AV accesses placed anywhere other 
than the arm were excluded. Pre-operative US vascular mapping is routinely used in all units 
aided by venography in patients at high risk for central vein stenosis, however vessel 
selection is not based on strict minimum diameter criteria and the decision ultimately resides 
with the operating surgeon. Patients were followed from the time of AV access placement 
and up until 31st December 2016 thus allowing a minimum 1 year of follow-up. Data on AV 
access use, patency, complications and procedures were determined through analysis of 
unitary electronic patient records or scrutiny of the clinical case records. The study was 
conducted under the auspices of the Scottish Renal Registry (SRR). The SRR is registered 
with the information commissioner under the terms of the data protection act via National 
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Service Scotland. As part of a national audit representing an ongoing quality improvement 
work-stream undertaken by SRR, formal ethics approval was not required. Information 
regarding the use of SRR data for quality improvement is displayed in all dialysis units in 
Scotland (http://www.srr.scot.nhs.uk/About/Patient-Confidentiality.pdf). 
 
Outcomes 
Patencies and other outcomes of interest were reported using recommended standards for AV 
hemodialysis accesses11. The primary endpoint was efficacy as assessed by a) successful AV 
access use and b) primary, primary-assisted, and secondary patencies at 1 year. Successful 
AV access use was defined as the ability of the AV access to be cannulated with 2 needles 
and achieve the prescribed dialysis for at least 75% of dialysis sessions over a minimum 
period of 30 days12. In the remaining patients, non-use was defined as AV access 
abandonment prior to use or less than 30 days of use. Patients not defined as having use or 
non-use (e.g. never initiated hemodialysis) were considered indeterminate. Primary patency 
was defined as the interval from the time of access placement until any type of intervention to 
maintain or restore patency, access thrombosis, or the time of measurement of patency; 
primary-assisted patency was defined as the interval from the time of access placement until 
access thrombosis, or the time of measurement of patency; and secondary patency was 
defined as the interval from the time of access placement until access abandonment, 
thrombosis, or the time of measurement of patency including preceding successful 
interventional or surgical procedures to maintain or re-establish patency11. Secondary 
endpoints were patency at 6 months, the natural history of patients following AV access 
creation and interventions by the end of the observation period. An AV access was defined as 
functional if it fulfilled the criteria for successful use and was still in use at the end of the 
follow-up. AV accesses were categorizes as being abandoned due to primary failure (i.e. 
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never used for dialysis or failed within 90 days of use) or late failure (i.e. failed after at least 
90 days of normal use). The time of abandonment was verified by the electronic patient 
record and it was the first time that an AV access was reported as 'failed' or 'abandoned'. In 
pre-dialysis patients, AV access maturation and patency were defined on the basis of physical 
examination findings, flow measurements, or duplex US. 
 
Statistical analysis 
Key parameters were summarised descriptively. Time to loss of patency was demonstrated 
using the Kaplan-Meier method11 with separate assessments for primary, primary-assisted, 
and secondary patency. Patients were censored at death, kidney transplantation, switch to 
peritoneal dialysis (PD), or loss to follow-up. Additional analyses were conducted with 
access stratified by location (upper vs. forearm and use of cephalic vs. basilic vein). A Cox 
proportional hazards model was created with time to final failure or access abandonment as 
the dependent variable. The complement of the Kaplan-Meier estimate (1-KM) was used to 
estimate the cumulative hazard function for AV access failure. Additional competing risk 
regression using the subdistribution hazard model13 was performed and the cumulative 
incidence competing risk (CICR) method14 was applied to estimate the cumulative incidence 
function for AV access failure. Competing events were death, kidney transplantation, or 
switch to PD. 
For all analyses, a p<0.05 was considered significant. The Stata Statistics Package (Stata/SE, 
version 15.0; StataCorp LLC, USA) was used for all analyses. 
 
Results 
There were 582 autogenous AV accesses created in 537 patients (Table 1). This was a 
predominantly Caucasian population, 60.1% were males and mean age at the time of AV 
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access creation was 60 (SD 14) years. Diabetes and vascular disease were common (more 
than 40% each) and significant comorbidity was present with a Charlson comorbidity index 
of ≥3 in 69.8% of the patients. 164 (28.2%) patients had previous AV access for 
hemodialysis, with a range of 1 to 5 procedures, and almost half of the patients had previous 
central venous catheterisation (CVC), with a range of 1 to 8. Mean follow-up was 11.8 (SD 
7.6) months, with a cumulative follow-up of 571 patient-years.   
During follow-up, 322 (55.3%) AV accesses were successfully used for hemodialysis and 
166 (28.5%) were not. For 94 (16.2%) AV accesses functional status could not be determined 
as the patients never initiated dialysis, died or were transplanted with a patent AV access 
(Table 2). The average time to AV access use was 96 (IQR 57-197) days. At the end of the 
follow-up, 287 (49.3%) AV accesses were patent (either functional or not yet used as patients 
were pre-dialysis) and 196 (33.7%) were abandoned mainly due to primary failure. Of these, 
48 (8.2%) AV accesses were abandoned in the first week after creation. During follow-up, 99 
patients (17.0%) were censored (including 48 who died, 44 transplanted, 5 switched to PD, 
and 2 lost to follow-up) while the AV access was patent (Table 2). From the 363 patients that 
were on hemodialysis at the end of the follow-up, 303 (83.5%) were dialysing via an AV 
access (autogenous or prosthetic) and 60 (16.5%) via CVC. A graph chart displaying the 
natural history of patients from the time of AV access creation and up to 1 year of follow-up 
is shown in Figure 1. In the pre-dialysis group, 116 (37.3%) patients were dialysing via the 
index AV access 1 year after creation compared with 131 (48.3%) patients in the dialysis-
dependent group.   
Interventions to maintain or restore patency were performed at a rate of 0.48 per patient-year 
(Table 2). Most interventions were angioplasties (67.6%) with only a small number of AV 
accesses requiring thrombectomy (4.4%). Stents were placed in AV accesses with recurrent 
stenoses resistant to angioplasty (4.0%), and in one case a stent was inserted following 
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thrombectomy. Of the 186 angioplasties, 116 (62.4%) were performed in outflow veins, 44 
(23.7%) in swing-points (39 juxta-anastomotic and 5 in cephalic arch), 14 (7.5%) in central 
veins and 12 (6.4%) in inflow arteries. All 11 stents were placed in outflow circuit [8 (72.7%) 
in outflow veins and 3 (27.3%) in central veins)]. Twenty nine (10.5%) AV accesses required 
surgical revision, mainly juxta-anastomotic reconstructions, and 37 (13.5%) required ligation 
of venous tributaries. The outflow vein was the predominant location of intervention with a 
total of 181 (63.1%) procedures followed by the anastomotic or juxta-anastomotic parts of the 
AV access with 53 (18.5%) procedures. From the 132 AV accesses requiring at least one 
intervention to promote maturation, 101 (76.5%) were ultimately successfully used for 
dialysis. 
At 1 year, the pooled primary patency was 48% (95% CI 44-52, n=234/582), primary-
assisted patency was 67% (95% CI 63-71, n=322/582), and secondary patency was 69% 
(95% CI 65-73, n=331/582). At 6 months, the primary patency was 62% (95% CI 58-66), 
primary-assisted patency was 74% (95% CI 70-77), and secondary patency was 76% (95% CI 
72-79) (Table 3, Figure 2a). In subgroup analyses of upper vs. forearm AV accesses, the 
primary, primary-assisted and secondary patency at 1 year was 51% (95% CI 45-56), 73% 
(95% CI 68-77) and 74% (95% CI 70-79) for upper arm vs. 43% (95% CI 35-50), 55% (95% 
CI 48-62) and 58% (95% CI 51-65) for forearm AV accesses, respectively (Table 3, Figure 
2b-d). In subgroup analyses of brachial-cephalic vs. brachial-basilic AV accesses, the 
primary, primary-assisted and secondary patency at 1 year was 57% (95% CI 51-63), 77% 
(95% CI 72-82) and 80% (95% CI 75-85) for brachial-cephalic vs. 35% (95% CI 26-45), 
62% (95% CI 52-71) and 65% (95% CI 55-73) for brachial-basilic AV accesses, respectively 
(Table 3). 
On univariable analyses, upper arm AV access (HR 0.54; 95% CI 0.41 to 0.72) was 
associated with prolonged secondary patency whilst previous AV access (HR 1.50; 95% CI 
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1.11 to 2.01) and previous ipsilateral CVC (HR 1.44; 95% CI 1.02 to 2.03) were associated 
with poorer secondary patency (Table 4). On multivariable analysis, upper arm AV access 
(HR 0.48; 95% CI 0.36 to 0.65) was an independent predictor of prolonged secondary 
patency whilst previous AV access (HR 1.49; 95% CI 1.06 to 2.07) was an independent 
predictor of poorer secondary patency. These associations remained unchanged when 
competing risks were taken into account in multivariable analysis (Table 4). 
The probability of AV access failure was 24% (95% CI 21-28) at 6 months and 31% (95% CI 
27-35) at 1 year when traditional survival analysis was applied to estimate the cumulative 
hazard function (Figure 3a). When competing risks analysis was implemented to estimate the 
cumulative incident function, the probability of AV access failure was 18% (95% CI 16-21) 
at 6 months and 23% (95% CI 20-27) at 1 year (Figure 3b). 
 
Discussion 
This is a contemporary national cohort of all AV access creation operations in a calendar year 
showing that AV access outcomes in a changing HD population are similar to historical 
reports despite the increased use of imaging and targeted endovascular approaches. The 
volume of activity was relatively high with a total of 582 autogenous AV accesses formed 
across the country. Using the conventional definition for successful AV access use of 
reproducible cannulation for 1 month of dialysis, 55% of patients used their AV access within 
1 year. A further 16% patients had a patent AV access when censored or at the end of the 
follow-up and were considered indeterminate. In an intention-to-treat analysis, where primary 
failures were included in estimation of patency, 69% (65-73) AV accesses were patent at 1 
year and 52% failed or required at least one intervention. Primary-assisted and secondary 
patency rates were similar suggesting that when thrombosis occurs, this commonly represents 
11 
 
a non-remediable underlying problem. From the multiple factors tested, upper arm AV 
accesses had prolonged patency especially if they were the patient’s first access.  
Determining a meaningful definition of optimal outcome for a patient is not straightforward. 
For example, only 60–70% of patients with chronic kidney disease who undergo pre-dialysis 
AV access placement initiate dialysis within 1 year. Definitions of outcomes that are based 
on AV access use are thus not applicable in 30-40% of these patients. In this study 166 (53%) 
pre-dialysis patients initiated dialysis within 1 year, of whom 116 (70%) did so via the index 
AV access. In the dialysis-dependent group 221 patients were receiving HD at 1 year, of 
whom 131 (59%) did so via the index AV access. 
As a consequence of high non-maturation rates ranging from 20-60%15-17, a significant 
proportion of the AV accesses encounter primary failure during the first weeks after 
surgery15, 18, 19 with more current data highlighting a higher risk of primary failure17. When 
patency rates are calculated starting at the day of first cannulation, primary failed AV 
accesses are not included introducing biases. In two meta-analyses of AV access patency 
reports covering >20 years of AV access creation, when primary failure was included in the 
calculation of patency rate, the primary and secondary patency rates were 60-64% and 71-
79% at 1 year, respectively17, 20. Although primary patency as determined by our data is lower 
than that reported in previous studies, secondary patency rates are similar (76% and 69% at 6 
and 12 months, respectively). In fact, an increased risk for primary patency loss can be 
expected in our population where routine monitoring programs are in place as adoption of 
AV access surveillance is known to result in increased intervention rates21.  
This study benefits from a comprehensive data collection system. In particular we had access 
to all radiological procedures and we were able to characterize the exact location and the 
intervention performed in all dysfunctional AV accesses. AV access thrombosis treatment 
success can range from 88 to 100%, with post-intervention primary patency rates ranging 
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from 9% to 49% at 1 year22-24. In our study, primary patency following treatment of 
thrombosis was 49% (22-71) at 1 year, however the difference between primary-assisted and 
secondary patency was only 2%. This indicates that interventions should be targeted to 
prolong the thrombosis-free access survival i.e. before a stenosis progresses to thrombosis. 
Undoubtedly this may translate to a more aggressive approach when a stenosis is identified. 
In AV accesses that fail to mature, early evaluation and aggressive treatment of correctable 
problems, mainly stenosis, resulted in 1-year primary patency from 68 to 74.7%25, 26. On the 
other hand, in functional AV accesses, although pre-emptive stenosis correction reduced the 
risk of thrombosis, it did not prolong the longevity of the access27.  
On multivariable analysis upper arm AV accesses and first attempt for an AV access creation 
were the only predictors of better cumulative patency. Indeed, there was a significant 
difference in patency rates between upper and forearm AV accesses, with 1-year patency of 
74% versus 58%, respectively. This trend is echoed by others18, 28-31 and has contributed in 
the shift from forearm to upper-arm AV accesses predominantly in the US32. Patients with 
previous failed AV access are susceptible to future AV access failure and this is conceivably 
related to the presence of pre-existing risk factors for failure or the occurrence of maladaptive 
vascular remodelling and neointimal hyperplasia following creation of the previous failed AV 
access33.Brachial-cephalic AV accesses had better patency rates compared to brachial-basilic 
and this is opposed to previous studies which have shown less primary failures for basilic 
vein AV accesses and similar cumulative access survival34-36. This finding should be 
interpreted with caution and may merely represent the practice of rarely using the basilic vein 
as a first option and thus the majority of these AV accesses were created in patients with 
previous failed VA procedures or poor cephalic options hence were representative of a cohort 
of patients with difficulties in establishing permanent access. Although not statistically 
significant, poorer outcomes were found for several known risk factors: patients on 
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hemodialysis at the time of AV access creation, previous dialysis catheters ipsilateral to the 
AV access arm and patients that did not have duplex US as part of their routine surveillance. 
Many studies are challenging the utility of 'fistula first' strategies in the older dialysis patient 
population, however age was not a predictor of patency when analysed as continuous (Table 
4) or binary variable (HR for patients ≥60 years 0.96; 95% CI 0.73 to 1.27 on univariable and 
1.10; 95% CI 0.82 to 1.46 on multivariable analysis). Previous studies have also failed to 
show that older patients and women were at significantly increased risk for AV access 
abandonment37, 38 suggesting that these are potential confounders. 
One of the key findings of this study brings the accepted concept of competing risks that is 
widely applied in other fields to that of AV access. Standard survival analysis and Cox 
proportional hazards models that are used to describe outcomes other than all-cause mortality 
in the presence of a significant and related competing risk may generate misleading results 
and this has been acknowledged to represent a problem that deserves more attention in the 
field of nephrology39. Censored subjects will be considered “at risk” for the outcome of 
interest for the duration of the study, yet deceased patients for instance are no longer at risk 
for AV access failure. By failing to account for the competing risk of death, Kaplan-Meier 
estimates will overestimate the probability of AV access failure. In our study 17% patients 
had a competing event (died, transplanted or switched to PD) and this alters the estimated 
probability of AV access failure. The probability of AV access failure was 31% at 1 year 
when cumulative hazard function was used, which is significantly higher compared to the 
23% probability of failure estimated with the cumulative incident function. 
The results from this study challenge the current clinical practices and may pave the road for 
future clinical trials with definitive strategies to prevent early failure. Despite a number of 
‘negative trials’ in HD (dose of dialysis40, statins41, cinacalcet42), we still have not conquered 
one of the single most important determinants of survival and quality of life: improving 
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technical and functional success of AV access in an increasingly comorbid population. We 
have demonstrated that in a non-selected population where 70% of patients had Charlson 
comorbidity index of 3 or more, the vast majority had previous access procedures and half of 
them required an intervention within 1 year of the index AV access creation, AV access 
outcomes were suboptimal. Nevertheless, these data clearly show that proximal versus distal 
AV access and avoidance of prior surgery are the key factors for success. This creates a case 
for an appropriately designed trial which will directly compare the outcomes of proximal 
versus distal AV access creation focusing on patient-specific factors rather than vessel 
selection or pharmacological interventions.  
Although observational, this study benefits from high-quality granular data that were 
captured manually through the databases used allowing for accurate assessment of AV access 
use, abandonment and procedure rates. In addition, by tracking of the patients' dialysis career 
we achieved detailed profiling which was graphically plotted. We analysed data from nine 
centres with heterogeneity of available resources and implementation of different policies 
which allows generalisability of our results. Although several previous observational studies 
have been performed on this topic, there is a dearth of data derived from European 
populations. Survival of AV accesses has been shown to differ across continents43; hence this 
study expands our current knowledge. 
Our study also has limitations. No unifying criteria between centres were applied to define 
AV access maturation and patency and duplex surveillance was routinely applied in four out 
of the nine renal units (n=230 AV accesses). We used an observational study design thus 
there is likely residual confounding due to patient characteristics (e.g., vessel size and quality, 
surgical experience) not available in the data sources used for this analysis. A centre-effect 
may have played a role in our observation as inclusion of dialysis centres with an insufficient 
number of AV access surgeries per year may have resulted in a lower number of functioning 
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AV accesses with a high failure to mature rate. However, all centres had a cohesive vascular 
access team in place and the value of this national dataset is that it reduces population 
specific, surgical skills specific and vessel selection specific variation that may be seen 
between individual units. Finally, access choice was not standardized, and although the 
majority of the patients had pre-operative duplex vessel assessment, the clinical or radiologic 
evaluation of patient suitability for an AV access may have varied by surgeon. 
 
Conclusion 
 Creating and maintaining an autogenous arteriovenous access for hemodialysis is a complex 
process subject to patient-specific characteristics, surgical expertise and vascular access 
infrastructure. Despite significant technical and medical advances in vascular access and 
associated increases in healthcare costs, patency rates in a non-selected contemporary 
population have not improved significantly. This should be taken into account in future 
clinical trial design where a more holistic range of endpoints should be endorsed, and where 
variables such as AV access site and cannulation techniques are included. 
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Table 1. Baseline characteristics. 
Patients 
 
N=537 
 
Male 323 (60.1%) 
Race 
     White Caucasian 514 (95.7%) 
     Asian 21 (3.9%) 
     African American 2 (0.4%) 
Comorbidities 
     Diabetes 223 (41.5%) 
     Cardiovascular disease 112 (20.9%) 
     Cerebrovascular disease 62 (11.5%) 
     Peripheral arterial disease 62 (11.5%) 
Charlson comorbidity index 
     2 162 (30.2%) 
     3-4 198 (36.9%) 
     >4 177 (32.9%) 
 
AV access procedures 
 
N=582 
Mean age at AV access creation (years; SD) 60 (14) 
     ≥60 years 301 (51.7%) 
Mean duration of follow-up (months; SD) 11.8 (7.6) 
     ≥12 months 331 (56.9%) 
     ≥18 months 145 (24.9%) 
Mean body mass index (kg/m2; SD) 28.6 (6.9) 
Hemodialysis at AV access creation 271 (46.6%) 
     Median hemodialysis vintage (months; IQR) 7.6 (2.6-27.5) 
Antiplatelet use 266 (45.7%) 
Anticoagulant use 45 (7.7%) 
At least one previous arteriovenous access 164 (28.2%) 
At least one previous central vein catheter 266 (45.7%) 
 
Data are n (%) unless stated otherwise 
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Table 2. Clinical outcomes and interventions after AV access creation. 
 
 
 Total AV accesses (N=582) 
Successful AV access use 
     AV access use 322 (55.3%) 
     AV access non-use 166 (28.5%) 
     Indeterminate 94 (16.2%) 
Natural history after AV access creationa 
     AV access functional 244 (41.9%) 
     AV access patent 43 (7.4%) 
     AV access abandonment 196 (33.7%) 
        Primary failure 173 (29.7%) 
        Late failure 23 (4.0%) 
     Death 48 (8.2%) 
     Transplantation 44 (7.6%) 
     Peritoneal dialysis 5 (0.9%) 
     Lost to follow-up 2 (0.3%) 
Interventions 
     Total procedures 275 
     Angioplasty 186 (67.6%) 
     Stent insertion 11 (4.0%) 
     Thrombectomy 12 (4.4%) 
     Revision 29 (10.5%) 
     Ligation of tributaries 37 (13.5%) 
     Interventions per patient-year 0.48 
Location of intervention 
     Inflow artery 22 (7.7%) 
     Outflow vein 181 (63.1%) 
     Swing-point 60 (20.9%) 
        Juxta-anastomotic 53 (18.5%) 
        Cephalic arch 7 (2.4%) 
     Central vein 24 (8.3%) 
 
Data are n (%) unless stated otherwise 
a By the end of the observation period 
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Table 3. AV access patencies. 
 Total AV 
accesses  
(N=582) 
Forearm AV 
accesses (N=196) 
Upper arm AV 
accesses (N=386) 
P-
valuea 
Brachial-cephalic 
AV accesses 
(N=273) 
Brachial-basilic 
AV accesses 
(N=107) 
P-
valueb 
 
Patency (%, 95% CI) 
     Primary patency 
        6 months 62% (58-66) 55% (47-62) 66% (61-71)  
0.005 
72% (66-77) 51% (41-60)  
<0.001         12 months 48% (44-52) 43% (35-50) 51% (46-56) 57% (51-63) 35% (26-45) 
     Primary-assisted patency 
        6 months 74% (70-77) 62% (55-69) 80% (76-84)  
<0.001 
84% (79-88) 69% (59-76)  
0.002         12 months 67% (63-71) 55% (48-62) 73% (68-77) 77% (72-82) 62% (52-71) 
     Secondary patency 
        6 months 76% (72-79) 65% (58-71) 82% (77-85)  
<0.001 
87% (82-90) 72% (63-80)  
0.001         12 months 69% (65-73) 58% (51-65) 74% (70-79) 80% (75-85) 65% (55-73) 
 
a Upper vs. Forearm 
b Brachial-cephalic vs. brachial-basilic 
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Table 4. Factors associated with secondary patency. 
 
 
Univariable analysis Cox regression analysis Competing risks analysis 
 
Hazard ratio (95% 
CI) 
P-value 
Hazard ratio (95% 
CI) 
P-value 
Subdistribution 
hazard ratio (95% 
CI) 
P-value 
Age, per year 0.99 (0.98 – 1.00) 0.25 1.00 (0.99 – 1.01) 0.94 1.00 (0.99 – 1.01) 0.99 
Female sex 1.05 (0.79 – 1.39) 0.76 1.20 (0.89 – 1.62) 0.22 1.21 (0.90 – 1.62) 0.22 
Diabetes 1.01 (0.76 – 1.34) 0.94 1.09 (0.82 – 1.46) 0.54 1.10 (0.82 – 1.48) 0.51 
Predialysis vs. hemodialysis 0.77 (0.58 – 1.02) 0.07 0.92 (0.66 – 1.29) 0.65 0.94 (0.67 – 1.33) 0.74 
Upper vs. forearm AV access 0.54 (0.41 – 0.72) <0.001 0.48 (0.36 – 0.65) <0.001 0.51 (0.38 – 0.69) <0.001 
Duplex surveillancea 0.76 (0.57 – 1.02) 0.07 0.77 (0.57 – 1.04) 0.09 0.78 (0.57 – 1.06) 0.11 
Proceduresb 1.00 (0.99 – 1.00) 0.11 1.00 (0.99 – 1.00) 0.16 1.00 (0.99 – 1.00) 0.38 
Previous AV access 1.50 (1.11 – 2.01) 0.007 1.49 (1.06 – 2.07) 0.02 1.48 (1.04 – 2.10) 0.03 
Previous ipsilateral CVC 1.44 (1.02 – 2.03) 0.03 1.30 (0.88 – 1.92) 0.19 1.23 (0.82 – 1.84) 0.31 
Antiplatelet use 0.98 (0.74 – 1.30) 0.91 0.93 (0.69 – 1.24) 0.61 0.93 (0.70 – 1.24) 0.62 
 
a Intention to treat (ITT) analysis 
b Time-varying covariate 
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Figure 1. Changes in patients’ status from the time of AV access creation and up to 1 year of follow-up divided by patients’ status at time of AV 
access creation a. Pre-dialysis and b. dialysis-dependent patients.  
24 
 
Figure 2. Kaplan-Meier curves for AV access patencies a. Primary, primary-assisted and secondary patencies of all AV accesses and b. primary, 
c. primary-assisted and d. secondary patency by AV access type (upper vs. forearm).
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Figure 3. Cumulative probability of AV access failure over time estimated by a. the cumulative hazard function derived from the complement of 
the Kaplan-Meier estimate (1-KM) and b. the cumulative incidence function derived from the cumulative incidence competing risk (CICR) 
method accounting for the presence of competing risks. 
 
